HomeCompareRMD vs EMN

RMD vs EMN: Dividend Comparison 2026

RMD yields 1.06% · EMN yields 4.60%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMN wins by $30.8K in total portfolio value
10 years
RMD
RMD
● Live price
1.06%
Share price
$220.03
Annual div
$2.33
5Y div CAGR
35.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$3,288.25
Full RMD calculator →
EMN
EMN
● Live price
4.60%
Share price
$72.55
Annual div
$3.34
5Y div CAGR
25.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62.5K
Annual income
$11,712.17
Full EMN calculator →

Portfolio growth — RMD vs EMN

📍 EMN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRMDEMN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RMD + EMN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RMD pays
EMN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RMD
Annual income on $10K today (after 15% tax)
$90.01/yr
After 10yr DRIP, annual income (after tax)
$2,795.01/yr
EMN
Annual income on $10K today (after 15% tax)
$391.32/yr
After 10yr DRIP, annual income (after tax)
$9,955.34/yr
At 15% tax rate, EMN beats the other by $7,160.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RMD + EMN for your $10,000?

RMD: 50%EMN: 50%
100% EMN50/50100% RMD
Portfolio after 10yr
$47.1K
Annual income
$7,500.21/yr
Blended yield
15.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EMN right now

RMD
Analyst Ratings
16
Buy
14
Hold
5
Sell
Consensus: Buy
Price Target
$295.88
+34.5% upside vs current
Range: $265.00 — $345.00
Altman Z
11.6
Piotroski
7/9
EMN
Analyst Ratings
20
Buy
14
Hold
1
Sell
Consensus: Buy
Price Target
$74.00
+2.0% upside vs current
Range: $70.00 — $79.00
Altman Z
2.3
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RMD buys
0
EMN buys
0
No recent congressional trades found for RMD or EMN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRMDEMN
Forward yield1.06%4.60%
Annual dividend / share$2.33$3.34
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR35.9%25.7%
Portfolio after 10y$31.7K$62.5K
Annual income after 10y$3,288.25$11,712.17
Total dividends collected$10.4K$36.8K
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusBuyBuy
Analyst price target$295.88$74.00

Year-by-year: RMD vs EMN ($10,000, DRIP)

YearRMD PortfolioRMD Income/yrEMN PortfolioEMN Income/yrGap
1← crossover$10,844$143.91$11,279$578.69$435.00EMN
2$11,801$198.21$12,835$766.75$1.0KEMN
3$12,901$273.96$14,758$1,025.04$1.9KEMN
4$14,185$380.39$17,176$1,384.65$3.0KEMN
5$15,709$531.20$20,272$1,893.11$4.6KEMN
6$17,556$747.16$24,315$2,624.76$6.8KEMN
7$19,845$1,060.53$29,716$3,698.58$9.9KEMN
8$22,757$1,522.63$37,106$5,310.02$14.3KEMN
9$26,567$2,217.64$47,493$7,789.38$20.9KEMN
10$31,715$3,288.25$62,530$11,712.17$30.8KEMN

RMD vs EMN: Complete Analysis 2026

RMDHealthcare

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Full RMD Calculator →

EMNMaterials

Eastman Chemical Company operates as a specialty materials company in the United States and internationally. The company's Additives & Functional Products segment offers hydrocarbon and rosin resins; organic acid-based solutions; amine derivative-based building blocks; metam-based soil fumigants, thiram and ziram based fungicides, and plant growth regulators; specialty coalescent, specialty and commodity solvents, paint additives, and specialty polymers; heat transfer and aviation fluids; insoluble sulfur and anti-degradant rubber additives; and performance resins. It serves transportation, personal care, wellness, food, feed, agriculture, building and construction, water treatment, energy, consumables, durables, and electronics markets. Its Advanced Materials segment provides copolyesters, cellulosic biopolymers, cellulose esters, polyvinyl butyral (PVB) sheets, and window and protective films, and aftermarket applied film products for value-added end uses in the transportation, durables, electronics, building and construction, medical and pharma, and consumables markets. The company's Chemical Intermediates segment offers methylamines and salts higher amines and solvents; Olefin and acetyl derivatives, ethylene, and commodity solvents; and primary non-phthalate and phthalate plasticizers, and niche non- phthalate plasticizers to the industrial chemicals and processing, building and construction, health and wellness, and agrochemicals. Its Fibers segment provides cellulose acetate tow, triacetin, cellulose acetate flake, acetic acid, and acetic anhydride for use in filtration media primarily cigarette filters; natural and solution dyed acetate yarns for use in consumables, and health and wellness markets; and wet-laid nonwoven media, specialty and engineered papers, and cellulose acetate fibers for transportation, industrial, agriculture and mining, and aerospace markets. Eastman Chemical Company was founded in 1920 and is headquartered in Kingsport, Tennessee.

Full EMN Calculator →
📬

Get this RMD vs EMN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RMD vs SCHDRMD vs JEPIRMD vs ORMD vs KORMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.